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Objective: Octreotide, a somatostatin analogue, has
been shown to prevent angiogenesis in diverse in
vitro models. We evaluated its effect on retinal neo-
vascularization in vivo, using a neonatal rat retino-
pathy model.
Methods: We used, on alternating days, hypoxia
(10%O2) and hyperoxia (50%02) during the first 14
days of neonatal rats, to induce retinal neovascu-
larization. Half of the rats were injected subcuta-
neously with octreotide 0.7 g/g BW twice daily. At
day 18 the eyes were evaluated for the presence of
epiretinal and vitreal hemorrhage, neovasculariza-
tion and epiretinal proliferation. Octreotide phar-
macokinetics and its effect on serum growth hormone
(GH) and insulin-like growth factor I (IGF-I) were
examined in 28 rats.
Results: Serum octreotide levels were 667 g/1 two
hours after injection, 26.4 g/1 after nine hours and
3.2g/1 after 14 hours. GH levels were decreased
by 40% (p=0.002) two hours after injection but
thereafter returned to baseline. IGF-I levels were un-
changed two hours after injection and were elevated
by 26% 14 hours after injection (p 0.02). Epiretinal
membranes were highly associated with epiretinal
hemorrhages (p < 0.001), while retinal neovasculari-
zation was notably associated with vitreal hemor-
rhages (p < 0.001).
Conclusions: Twice-daily injections of octreotide
failed to produce sustained decrease in serum GH,
but produced rebound elevation of serum IGF-I.
Accordingly, no statistically significant effect of in-
jections on retinal pathology was noted. This find-
ing, however, does not contradict our assumption
that GH suppression may decrease the severity of
retinopathy.
Keywords: Retinopathy of prematurity, angiogenesis, insulin-
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INTRODUCTION
Retinal neovascularization is a common feature
of several eye diseases characterized by retinal
hypoxia, such as proliferative diabetic retino-
pathy (PDR) and retinopathy of prematurity
(ROP). While the underlying pathology may be
different in these conditions, the neovascular pro-
cess itself leads to destruction of normal retina
and eventually causes blindness.
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Growth hormone (GH) and insulin-like
growth factor I (IGF-I) have been implicated in
the pathogenesis of PDR (Lundbaek et al., 1970;
Dills et al., 1991). IGF-I has been shown to have
angiogenic properties in animal models (Grant
et al., 1993), and serum IGF-I levels have been
reported to be elevated in patients with PDR
(Merimee, Zapf and Froesch, 1983). High vitre-
ous levels of IGF-I and IGF binding proteins
(IGFBPs) were found in patients with neovas-
cular eye disease related to diabetes and to other
ischemic retinal conditions (Meyer-Schwickerath
et al., 1993). In addition, a recent study demon-
strated the essential role of GH and IGF-I in the
development of retinal neovascularization in the
ROP model in mice (Smith et al., 1997).
Decades ago, before the advent of lasers,
elimination of GH production by pituitary
ablation was an accepted therapy for PDR
(Bradley, Rees and Fager, 1965). This approach
was abandoned later because of obvious draw-
backs, although several studies showed its ef-
fectiveness (Kohner et al., 1972). Pharmacological
inhibition of the GH secretion was shown to be
an effective substitute for hypophysectomy in
treatment of clinical PDR (McCombe et al., 1991)
and experimental ROP (Smith et al., 1997).
Octreotide, a long-acting somatostatin analo-
gue, is a potent inhibitor of GH secretion with
a plasma half-life of 90 minutes (Bauer et al.,
1982). Octreotide can be used to lower GH and
IGF-I levels (Plewe et al., 1987). In addition,
octreotide has been shown to have direct anti-
angiogenic properties in human retinal endo-
thelial cells culture (Grant, Caballero and
Millard, 1993) and in the vascular growth mod-
el of the chick-embryo chorioallantoic mem-
brane (Woltering et al., 1991). Octreotide was
tested in human clinical trials for treatment of
both early (Kierkegaard et al., 1990) and severe
PDR (Mallet et al., 1992; Lee et al., 1988). Though
several positive trends were shown in these
studies, the small size of the study groups
and lack of adequate controls do not allow us
to draw results. We studied the impact of
systemic octreotide treatment on retinal neo-
vascularization in a neonatal rat ROP model in
which we demonstrated a possible role of the
retinal IGF system in ischemia-induced neovas-
cularization (Averbukh et al., 1998).
METHODS
Animals
Fifty-six neonatal Sabra rats (provided by the
Harlan Laboratories, Jerusalem, Israel) were
divided into experimental groups of eight to
ten animals from mixed litters, not divided ac-
cording to gender. At the age of one day the
group with the lactating mother were placed
in an incubator with a controlled oxygen con-
centration. The lactating rats had free access
to standard rat chow and tap water. All the
animals were maintained and treated in ac-
cordance with the Association for Research
in Vision and Ophthalmology statement on the
use of animals in ophthalmic and vision re-
search. Retinal neovascularization was induced
by alternating oxygen concentrations as pre-
viously described (Reynaud and Dorey, 1994;
Penn, Tolman and Lowery, 1993). Briefly, the
animals were exposed on alternating days to
hypoxia (10% O2-24h) and hyperoxia (50%
O2-24h) during their first 14 days, followed
by four days in room air. Hypoxia was produced
by mixing air with nitrogen, and hyperoxia by
mixing air with oxygen. A minimal flow of two
liters per minute was maintained. Half of the
rats were injected subcutaneously with octreo-
tide 0.7 tg/g BW twice daily, while the other
half were injected with saline during the whole
period. At day 18 the rats were anesthetized
with ether and sacrificed. The eyes were enu-
cleated and placed in formaldehyde. To evalu-
ate the effect of octreotide injection on GH and
IGF-I levels, we checked the serum levels in
another 28 animals on days 7 (11 animals) and
14 (17 animals).OCTREOTIDE FAILS TO INHIBIT NEOVASCULARIZATION 41
Evaluation of Neovascularization-associated
Changes
In the neonatal ROP model, high oxygen lev-
els impede the normal vascularization process
(Chang-Ling et al., 1992) and induce vaso-ob-
literation (Pierce, Foley and Smith, 1996), thus
creating avascular areas in the periphery of the
retina. These areas are prone to ischemia when
the oxygen level is lowered. Severe hypoxia is
also associated with pre-retinal and vitreal .hem-
orrhages in neonatal rats. We observed sev-
ere intraocular hemorrhages in neonatal rats
after 24 hours’ exposure to hypoxia, suggesting
that these hemorrhages are primary phenom-
ena and not secondary to neovascularization (un-
published data). Blood on the retina, as well as
ischemia-associated factors, may cause epiretinal
proliferation and neovascularization which are
typical for many retinopathies, such as ROP and
diabetic retinopathy. These morphologic changes
were the subject of our study when comparing
the treated animals with the controls.
Each formalin-fixed, paraffin-embedded eye-
ball was examined for existence of gross pathol-
ogy. Then it was sliced using coronal cuts starting
from the optic nerve and ending close to the lim-
bus. If intraocular hemorrhages were noted, cuts
were made through them. Otherwise, ten repre-
sentative histological slides were prepared skip-
ping approximately equal numbers of cuts in
between. The slides were stained with hematox-
ylin-eosin and examined and scored in a masked
fashion by one examiner. Each eye was assessed
for various manifestations of retinal disease. We
looked for epiretinal hemorrhages (RH) (defined
as blood trapped between the retina and the
posterior hyaloid face), vitreal hemorrhages (VH)
(blood cells dispersed in the vitreous), epireti-
nal proliferation (proliferative vitreoretinopathy,
PVR) and neovascularization (NV). We defined
our findings as NV only when we saw discrete
blood vessels on the inner side of the internal
limiting membrane (Fig. 1A), while the finding
of fibrovascular proliferation and membrane for-
mation inside the vitreous cavity (Fig. 1B) was
defined by us as PVR. This separation of the pro-
liferative changes into NV and PVR was dic-
tated by our suspicion that we are seeing two
separate phenomena with different pathogenesis.
Each manifestation was given a score between
0 (non-existent) and 3 (severe) according to the
number of slides containing the specific path-
ology and the subjective perception of the
severity of pathology. For example, if neovas-
cularization was seen only on one slide and
was of limited extent it was assigned a score of
one. The statistical significance of the difference
between the scores was evaluated using the
Mann-Whitney Rank Sum Test. Correlation
between RH and VH on the one hand and PVR
and NV on the other hand was evaluated using
the Spearman Rank Order Correlation test. All
statistical analysis was performed using Sigma-
Stat for Windows software (Jandel Corporation,
San Rafael, CA).
Serum Octreotide, GH and IGF-I Levels
Serum octreotide, GH and IGF-I blood levels
were evaluated 2 hours after subcutaneous in-
jection of 10 tg octreotide in five 7-day-old ani-
mals with an average weight of 15g (0.7 tg/g
BW). Five control animals of the same age and
weight were injected with saline. Similarly, the
levels were measured in seventeen 14-day-old
animals with an average weight of 30 g after in-
jection of 20 tg of octreotide. Five animals were
sacrificed 9 hours after injection, and four ani-
mals 14 hours after injection. Eight controls of
similar weight and age were injected with saline.
Average levels of octreotide, GH and IGF-I were
calculated for each group. We used a one-tail
t-test for statistical analysis.
Serum rat growth hormone (rGH) was meas-
ured by radioimmunoassay (RIA) using a speci-
fic polyclonal rabbit rGH antibody and rGH
as standard. The ingredients for the RIA were
obtained from Amersham (Amersham Inter-
national, Amersham, Bucks, UK). Intra- and42 E. AVERBUKH et al.
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FIGURE Typical findings in the affected eyes. Slide A illustrates big epiretinal hemorrhage (arrows) with epiretinal
membrane formation around it. Some hemosiderin spots (arrow heads) are seen inside the hemorrhage, indicating the long-
standing nature of the bleeding. Slide B shows vitreous hemorrhage (arrows) with retinal neovascularization (arrow heads).
Hematoxylin-eosin stain, magnification x 10. (See Color Plate I).
interassay coefficients of variations were less
than 5% and 10% respectively. Serum IGF-I
was measured after extraction with acid-metha-
nol (30tl serum and 7501 acid methanol)
(Furlanetto and Marino, 1987). The mixture was
incubated for two hours at room temperature,OCTREOTIDE FAILS TO INHIBIT NEOVASCULARIZATION 43
centrifuged, and 25 gl of the supernatant was
diluted 1:200 before analysis. Serum IGF-I was
measured by RIA using a polyclonal rabbit anti-
body (Nichols Institute Diagnostics, San Juan
Capistrano, Calif., USA) and recombinant hu-
man IGF-I as standard (Amersham Interna-
tional, Amersham, Bucks, UK). Mono-idionated
IGF-I 125I-(31Tyr)-IGF-I was obtained from Novo-
Nordisk A/S Bagsvaerd, Denmark. When expos-
ing the serum extract to western ligand blotting
(WLB), no IGFBPs could be identified and
furthermore, semilog linearity of biosynthetic
IGF-I and serum extracts was seen, indicating
antigen similarity and the fact that no IGFBPs
interfered in the RIA. Intra- and interassay co-
efficients of variations were below 5 and 10%
respectively.
Serum octreotide was measured by RIA as
previously described (frskov, Thomsen and
Yde, 1968). Intra- and interassay coefficients
of variations were less than 5% and 10% for
all assays.
calculate the biological half-life time of octreo-
tide in our experiment we compared the octreo-
tide level two hours after injection with that
nine hours after injection. The serum level was
reduced from 667.0 gg/1 to 26.4 gg/1 in these sev-
en hours (420 minutes), which is less than five
[log2(667.0/26.4) =4.66] half-lives, thus, a half-
life time of approximately 90 minutes (420min/
4.66=90.1min.). Similarly, basing the calcula-
tion of octreotide half-life time on the difference
between the octreotide level at 9 hours and its
level at 14 hours results in a half-life time of
98 minutes.
Serum GH levels were decreased by 40%
(p 0.002) two hours after injection of octreotide
as compared with saline injected animals (Tab.
I). However, 9 and 14 hours after injection, GH
level was comparable in the octreotide and the
control groups. Serum IGF-I level was similar in
the treated and the control groups two hours
after injection, but was elevated in the treated
group 9 and 14 hours after injection (by 19% and
26%, p 0.06 and p 0.02 respectively).
RESULTS
Fifty-two eyes of 26 animals were examined in
the treatment group and 59 eyes of 30 animals in
the control group (one eye was not suitable for
histologic preparation).
Serum Octreotide, GH and IGF-I Levels
Octreotide levels were high two hours after
injection, but much lower later (Tab. I). To
Histologic Findings
The scores of histologic findings in the eyes
are summarized in Table II. Epiretinal and vi-
treal hemorrhages were the most frequently ob-
served findings in both the octreotide-treated
and the control groups with approximately 45%
of the eyes affected by each one of them and
70% affected by any of them. PVR was less com-
mon, affecting less than 40% of the eyes in each
group. NV was found only in 35% of the
octreotide-treated and in 27% of the control
TABLE Octreotide, GH and IGF-I levels after injection of octreotide
Time
after Age Octreotide
injection n (days) ktg/1
GH
gg/1
GH IGF-I
% of IGF-I % of
control gg/ control
Control 6 7 0
2 hours 5 7 667.0+ 42.5*
Control 8 14 0
9 hours 5 14 26.4 4- 5.1
14 hours 4 14 3.2 4- 0.7
73.7 4- 8.7 100 4-12 66.8 4- 7.6 100 4-11
44.6 4- 8.4t 60 4-11 66.4 4- 9.0 99 4-13
49.5 4-19.5 100 4- 39 77.6 4- 8.9 100 4-11
48.3 4-11.2 98 4- 27 92.4 4-14.2 119 4-18
41.3 4-18.1 83 4- 37 98.0 4-13.1 126 4-17
*Values are given as mean 4- SEM; p 0.002; *p 0.02.44 E. AVERBUKH et al.
TABLE II Scoring of findings in the eyes of the octreotide-treated and the control groups
Grade of
severity RH* VH* PVR* NV*
Octreotide
Control
None 56% (29) 54% (28) 61% (32) 65% (34)
13% (7) 19% (10) 12% (6) 10% (5)
2 12% (6) 6% (3) 19% (10) 12% (6)
3 19% (10) 21% (11) 8% (4) 13% (7)
None 54% (32) 58% (34) 64% (38) 73% (43)
1 26% (15) 22% (13) 19% (11) 14% (8)
2 10% (6) 8% (5) 15% (9) 5% (3)
3 10% (6) 12% (7) 2% (1) 8% (5)
Epiretinal hemorrhage (RH), vitreal hemorrhages (VH), proliferative vitreo-retinopathy (PVR) and neovascular budding (NV). Numbers are
presented as percent of total. Absolute numbers are given in parentheses. None of the differences reached a statistical significance.
eyes. The intraobserver error for scoring of dif-
ferent findings was 5-10%.
Using the Spearman Rank Order Correlation
test we found a strong association between the
presence of PVR and epiretinal hemorrhages
p < 0.001) but not vitreal hemorrhages p 0.9).
NV, on the other hand, was strongly associat-
ed with vitreal hemorrhages (p < 0.001) but not
with epiretinal hemorrhages p 0.27).
The score of neovascularization-associated
changes (PVR and NV) was higher in the octreo-
tide group than in the control group (Tab. II);
this difference, however, was not statistically sig-
nificant. Severe (grade 3) changes were slight-
ly more common in the octreotide-treated group
(Tab. II).
DISCUSSION
We demonstrated that twice-daily injections of
octreotide failed to induce sustained inhibition
of GH secretion and a reduction in serum IGF-I
in neonatal rats, while pharmacological serum
levels of octreotide were achieved. Furthermore,
retinal neovascularization was not inhibited. If
anything, severe (grade 3) manifestations of re-
tinal neovascularization were more common
in the octreotide-treated group than in the con-
trol group. These findings are in contrast with
our hypothesis, based on in vitro studies, that
octreotide prevents hypoxia-induced neovascu-
larization either directly or by lowering GH and
IGF-I levels.
The strong correlation between RH and PVR
on the one hand, and between VH and NV on
the other hand, is of interest and may point to
some underlying pathophysiology in our mod-
el. While NV was observed mostly in the peri-
phery of the retina (Fig. 1A), on the border of the
area which is typically affected by hypoxia in
the ROP model, the PVR was found mainly in
the posterior pole, associated with epiretinal he-
morrhages. This finding supports our theory
that the proliferative vitreoretinopathy (PVR)
is induced by epiretinal hemorrhage (RH), thus
should not necessarily originate from the peri-
phery of the retina, while "pure" neovasculari-
zation (NV) seen on Figure 1B is probably
induced by hypoxia-related growth factors
produced by adjacent avascular retina, typically
in the periphery. Bleeding may either cause
epiretinal proliferation directly or may be a mar-
ker of severe retinal ischemia that is trigger-
ing epiretinal proliferation through a variety of
growth factors. In any case, the sub-group of
eyes with intraocular hemorrhages is specifical-
ly prone to epiretinal proliferation. We should
stress that our definition of neovasculariza-
tion was different from that used by some oth-
er groups. We defined neovascularization as a
gross histological finding of blood vessels on the
inner side of internal limiting membrane, while
Smith et al. (1997) considered every nucleus ofOCTREOTIDE FAILS TO INHIBIT NEOVASCULARIZATION 45
vascular endothelial cell at the same location
as evidence of neovascularization. Our way of
evaluation is less sensitive, but has a greater
clinical implication.
The achieved octreotide half-life of 90 minutes
fits well with the previously reported half-life
time of the drug (Bauer et al., 1982). We evaluated
the effect of octreotide in 7- and 14-day animals,
since it is at this age that the avascular retina is
reacting to ischemia by up-regulation of IGF-
I receptor and IGF binding proteins 2 and 3
(Averbukh et al., 1998). It was impossible to take
blood samples from the actual experimental ani-
mals without severely affecting them by stress
and anemia. On the other hand, taking blood
samples at the time of sacrifice (18 days) was
probably irrelevant since the course of the neo-
vascularization process is determined much
earlier.
The primary effect of octreotide on neovascu-
larization is mediated, at least to some extent,
by GH secretion inhibition. GH levels were sig-
nificantly reduced two hours after injection,
but returned to normal nine hours after injection.
This very brief suppressive effect on GH lev-
els is in accordance with previously published
data (Wurzburger et al., 1992). However, even two
hours after injection, the achieved high level of
octreotide failed to reduce serum IGF-I levels. It
is of interest that treatment with octreotide at
similar dose prevented kidney hypertrophy in
diabetic rats (Flyvbjerg et al., 1989) while failing
to change significantly serum levels of GH or
IGF-I. Smith et al., showed recently that lower-
ing of GH by another somatostatin analogue is
effective in preventing hypoxia-induced neovas-
cularization in the ROP model in mice. How-
ever, in spite of the demonstrated inhibition of
GH secretion, athigher levels of somatostatin ana-
logue there was a paradoxical relative increase
in serum IGF-I levels that stayed unexplained
(Smith et al., 1997).
Octreotide was shown to have a direct inhi-
biting effect on IGF-I production in addition to
its effect through the inhibition of GH secretion
(Heyer et al., 1989). It was previously reported
that in cultured GH stimulated hepatocytes,
IGF-I mRNA levels were significantly reduced
in the presence of low octreotide concentrations
(0.3 and 3gg/1) while high concentrations of
octreotide (30 and 300gg/1) had no effect on
IGF-I mRNA abundance (Serri et al., 1992). In
the present study, octreotide was injected at 12-
hour intervals; therefore the lowest serum level of
octreotide, just before the next injection, was
approximately 6.6 gg/1 (extrapolated) whichmay
be still too high for a direct suppressive effect
on IGF-I production but too low for suppression
ofGH secretion. Moreover, withdrawal of octreo-
tide, like somatostatin withdrawal, may generate
a pulsatile GH release (Cella et al., 1996) which
may explain the elevation of IGF-I levels at 9 and
14 hours after injection. Fluctuations in IGF-I
levels, secondary to rebound elevation of GH
after a brief suppression, may have a deleterious
effect on retinal vasculature, promoting rather
than suppressing neovascularization.
Finally, octreotide was found to have direct
antiangiogenic properties in human retinal en-
dothelial cell (HREC) culture (Grant et al., 1993b)
and in a vascular growth model of the chick-
embryo chorioallantoic membrane (Woltering
et al., 1991). In cell culture of HREC stimulat-
ed by IGF-I and bFGF, [3H]thymidine incorpo-
ration was inhibited by octreotide (Grant et al.,
1993b). The dose-effect curve showed that an
octreotide level of 1.6gg/1 caused 15% inhibi-
tion, 16 gg/1 caused 35% inhibition and 164 gg/1
caused 60% inhibition. In our experiment, octreo-
tide serum level was between a few gg/1 and a
few hundreds gg/1 during the whole 12-hour
interval between injections. Inhibition of angio-
genesis, however, was not achieved.
In conclusion, twice-daily injections of octreo-
tide did not prevent hypoxia-related neovascu-
larization in our model. It is possible, however,
that the therapeutic range of octreotide is of cri-
tical importance, and that the great variability
of octreotide levels achieved in our study due
to twice-daily injections is not suitable for a46 E. AVERBUKH et al.
sustained effect. Furthermore, fluctuations in se-
rum octreotide level may have caused the ob-
served increase in neovascularization-related
changes in the treated group. Continuous infu-
sion of octreotide and other somatostatin analo-
gues with a longer half-life that better suppress
GH secretion may still be effective in preventing
neovascularization.
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